Bupivacaine controlled release - DURECT Corporation

Drug Profile

Bupivacaine controlled release - DURECT Corporation

Alternative Names: Optesia; POSIDUR; POSIMIR; SABER®-bupivacaine

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; Takeda Pharmaceuticals International GmbH
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 29 Feb 2016 Efficacy data from a phase IIb trial in Postoperative pain released by DURECT corporation
  • 19 Oct 2015 DURECT initiates enrolment in the phase III PERSIST trial for Postoperative pain in USA (SC) (NCT02574520)
  • 09 Oct 2015 DURECT plans the phase III PERSIST trial for Postoperative pain in USA (SC) (NCT02574520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top